Agenda

Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for chronic lymphocytic leukemia (CLL). Each event will employ an identical format that will include the following elements:

• Moderator Dr Neil Love and a featured participating clinical investigator
• Discussion of participating faculty treatment recommendations
• Review of available clinical research findings
• Community oncologist case presentations
• Interactive audience polling & extensive Q&A

Module 1: Optimal Integration of Venetoclax and BTK Inhibitors into the Front-Line Setting

Module 2: Management of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Target Audience
These activities are intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of chronic lymphocytic leukemia (CLL).

Learning Objectives

• Recall the incidence, prognostic significance and clinical implications of select biomarkers and chromosomal abnormalities that have been associated with a diagnosis of CLL, and use this information to develop evidence-based testing algorithms in general oncology practice.
• Individualize the selection of systemic therapy for patients with newly diagnosed or relapsed/ refractory CLL, considering clinical presentation, biomarker profile, coexisting medical conditions, psychosocial status and, where applicable, prior therapeutic exposure.
• Discuss available Phase III data demonstrating the superior efficacy and safety of Bruton tyrosine kinase (BTK) inhibition compared to standard chemoimmunotherapy as first-line therapy for patients with CLL, and use this information to discern how this strategy can be optimally integrated into nonresearch treatment.
• Appraise the Phase III data supporting the recent FDA approval of acalabrutinib for newly diagnosed or previously treated CLL, and identify patients for whom treatment with this agent may be appropriate.
• Compare and contrast the mechanisms of action, efficacy and safety of approved BTK inhibitors for the treatment of CLL to determine the current and/or potential utility of each in clinical practice.
• Assess the FDA approval of venetoclax in combination with obinutuzumab as front-line therapy for CLL, and determine how to appropriately integrate this regimen into current treatment decision-making.
• Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies in the management of CLL.
• Recognize the biologic rationale for, available research evidence with and ongoing clinical trials evaluating the use of chemotherapy-free combinations in the management of newly diagnosed and progressive CLL, and identify patients who may be suitable candidates for these approaches in or outside of an ongoing research study.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Dr Wierda has no relevant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr Davids — Advisory Committee: AbbVie Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeiGene, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, MEI Pharma Inc, Merck, Novartis, Pharmacyclics LLC, an AbbVie Company, Verastem Inc, Zentalis Pharmaceuticals; Contracted Research: AbbVie Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, MEI Pharma Inc, Novartis, Pharmacyclics LLC, an AbbVie Company, Surface Oncology, TG Therapeutics Inc, Verastem Inc. Dr Flinn — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene, Gilead Sciences Inc, Great Point Partners LLC, Iksuda Therapeutics, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, MorphoSys, Nurix Therapeutics Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, ScienceCurio, Seagen Inc, Takeda Oncology, Unum Therapeutics, Verastem Inc, Vincere Biosciences Inc, YL-Pharma Co Ltd; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Agios Pharmaceuticals Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, BeiGene, Calithera Biosciences, Celgene Corporation, Constellation Pharmaceuticals, Curis Inc, F Hoffmann-La Roche Ltd, FORMA Therapeutics, Forty Seven Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, IGM Biosciences Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Karyopharm Therapeutics, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, MorphoSys, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, Rhizen Pharmaceuticals SA, Roche Laboratories Inc, Seagen Inc, Takeda Oncology, Teva Oncology, TG Therapeutics Inc, Trillium Therapeutics Inc, Triphase Research & Development Corp, Unum Therapeutics, Verastem Inc. Prof Gribben — Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Janssen Biotech Inc, Karyopharm Therapeutics, Kite, A Gilead Company, MorphoSys, Novartis; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Janssen Biotech Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP. Dr Hill — Advisory Committee and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech, a member of the Roche Group, Kite, A Gilead Company, Novartis; Contracted Research: AbbVie Inc, Celgene Corporation, Genentech, a member of the Roche Group, Kite, A Gilead Company, Takeda Oncology. Dr Jain — Advisory Committee and Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics SA, AstraZeneca Pharmaceuticals LP, BeiGene, Genentech, a member of the Roche Group, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company, Precision BioSciences, Servier, TG Therapeutics Inc; Contracted Research: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics SA, Aprea Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cellectis, Fate Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Precision BioSciences, Servier; Data and Safety Monitoring Board/Committee: Janssen Biotech Inc. Dr Kahl — Advisory Committee: AstraZeneca Pharmaceuticals LP; Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, TG Therapeutics Inc; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, BeiGene, Celgene Corporation, Genentech, a member of the Roche Group; Data and Safety Monitoring Board/Committee: Celgene Corporation. Dr Mato — Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Johnson & Johnson Pharmaceuticals, Octapharma, Pharmacyclics LLC, an AbbVie Company; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Johnson & Johnson Pharmaceuticals, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Octapharma, Pharmacyclics LLC, an AbbVie Company, Sunesis Pharmaceuticals Inc, TG Therapeutics Inc; Data and Safety Monitoring Board/Committee: Celgene Corporation, TG Therapeutics Inc. Dr Pagel — Consulting Agreements: AstraZeneca Pharmaceuticals LP, BeiGene, Gilead Sciences Inc, Takeda Oncology. Dr Rogers — Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, AstraZeneca Pharmaceuticals LP, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc; Travel: AstraZeneca Pharmaceuticals LP. Dr Sharman — Advisory Committee, Consulting Agreements and Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc. Dr Siddiqi — Advisory Committee: Celgene Corporation, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Pharmacyclics LLC, an AbbVie Company; Data and Safety Monitoring Board/Committee: BeiGene; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company. Dr Smith — Advisory Committee: AbbVie Inc, Janssen Biotech Inc; Contracted Research: Karyopharm Therapeutics; Speaker's Bureau: AstraZeneca Pharmaceuticals LP, EUSA Pharma, Kite, A Gilead Company. Dr Woyach — Advisory Committee: AbbVie Inc, ArQule Inc, Janssen Biotech Inc; Consulting Agreements: AbbVie Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Data and Safety Monitoring Board/Committee: Gilead Sciences Inc.

SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Commercial Support
These activities are supported by educational grants from AbbVie Inc and AstraZeneca Pharmaceuticals LP.